Published in Am J Gastroenterol on December 06, 2016
Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. Dig Dis Sci (2017) 0.75
Diabetes and the Small Intestine. Curr Treat Options Gastroenterol (2017) 0.75
Diabetes Mellitus and the Colon. Curr Treat Options Gastroenterol (2017) 0.75
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol (2005) 2.17
Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol (2014) 2.09
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther (2007) 2.08
The functional gastrointestinal disorders and the Rome II process. Gut (1999) 1.97
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol (2009) 1.73
Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil (2008) 1.58
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol (2007) 1.57
Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci (2009) 1.50
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) 1.50
Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol (2001) 1.47
Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil (2010) 1.29
Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil (2010) 1.26
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil (2014) 1.09
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci (2011) 1.06
Colonic dysfunction in diabetes mellitus. Gastroenterology (1980) 1.05
Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol (1994) 1.05
Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci (1998) 0.85
How important are the disturbances of lower gastrointestinal bowel habits in diabetic outpatients? Am J Gastroenterol (2001) 0.80
Colorectal manifestations of endocrine disease. Dis Colon Rectum (1995) 0.80
Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon. Korean J Physiol Pharmacol (2014) 0.79
Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. Curr Med Res Opin (2016) 0.79